Holen Sie sich die Stockscreener-App
9.36
2.80%
-0.27
Schlusskurs vom Vortag:
$9.63
Offen:
$9.5
24-Stunden-Volumen:
9,029
Relative Volume:
1.04
Marktkapitalisierung:
$662.48M
Einnahmen:
$370.44M
Nettoeinkommen (Verlust:
$12.19M
KGV:
54.32
EPS:
0.1723
Netto-Cashflow:
$50.74M
1W Leistung:
-4.39%
1M Leistung:
-11.70%
6M Leistung:
-45.99%
1J Leistung:
-34.91%
1-Tages-Spanne:
$9.31
$9.515
1-Wochen-Bereich:
$9.31
$10.03
52-Wochen-Spanne:
$9.31
$21.34
Pharming Group Nv Adr Stock (PHAR) Company Profile
Firmenname
Pharming Group Nv Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare PHAR vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHAR
Pharming Group Nv Adr
|
9.36 | 662.48M | 370.44M | 12.19M | 50.74M | 0.1723 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pharming Group Nv Adr Stock (PHAR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-12-09 | Eingeleitet | Jefferies | Buy |
Pharming Group Nv Adr Aktie (PHAR) Neueste Nachrichten
Zai Lab LimitedADR Peer Comparison – Compare with Others - valueresearchonline.com
PHAR Q2 2026 Earnings: EPS Falls 90% Short of ConsensusAnalyst Drop Coverage - careplusvn.com
PHAR Q2 2026 Earnings: EPS Falls 90% Short of ConsensusEarnings Season Preview - dars.gov.et
PHAR Q2 2026 Earnings: EPS Falls 90% Short of ConsensusBalance Sheet Strength - dars.gov.et
Pharming Group (PHAR) Slips 3.22% to $11.11: Key Support Zone in FocusHagopian Line - careplusvn.com
Pharming Group (PHAR) Slips 3.22% to $11.11: Key Support Zone in FocusDescending Triangle - dars.gov.et
Pharming Group (PHAR) Slips 3.22% to $11.11: Key Support Zone in FocusOversold Bounce Ideas - dars.gov.et
XORTX Therapeutics Inc. (XRTX) Peer Comparison – Compare with Others - Value Research
Pharming (PHAR) Quarterly Results: The EPS Result Is Below Expectation in the Latest Session; Investor Response: Shares Move Lower 0.30% in the Current UpdateSlow Growth Warning - dars.gov.et
Pharming (PHAR) EPS and Revenue: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; After Earnings: The Market Price Declines 1.43% on the DayEarnings Preview - dars.gov.et
Pharming (PHAR) EPS and Revenue: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; After Earnings: The Market Price Declines 1.43% on the DayMargin Expansion Trends - dars.gov.et
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 93.0% in July - MarketBeat
Pharming Group (PHAR) Slides 5.1% to $11.72 as Rare-Disease Biotech Faces Selling PressureTrading Ideas - careplusvn.com
Pharming Group (PHAR) Slides 5.1% to $11.72 as Rare-Disease Biotech Faces Selling PressureInsider Selling Alerts - dars.gov.et
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by Brokerages - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Gap DownShould You Sell? - MarketBeat
Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Pharming (PHAR) Q2 2026 Earnings: 90% EPS Miss Overshadowed by Resilient Share PriceRevenue Warning Signal - careplusvn.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pharming Grou - The National Law Review
Pharming Group (PHAR) Securities Investigation NoticeLevi & Korsinsky - Sahm
Pharming Group (NASDAQ:PHAR) Shares Gap UpTime to Buy? - MarketBeat
Pharming Group (PHAR) Advances 1.93% to $10.01, Approaches Key Resistance at $10.51IV Spike - careplusvn.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Q3 EPS Estimates for Pharming Group Lowered by HC Wainwright - MarketBeat
PHAR Q2 2026 Earnings: Marginal EPS Miss Triggers 15.5% SelloffCFO Commentary Report - careplusvn.com
Pharming Group (NASDAQ:PHAR) Shares Gap Down Following Weak Earnings - MarketBeat
PHAR Q2 2026 Earnings: Marginal EPS Miss Triggers 15.5% SelloffSurprise Factor Analysis - dars.gov.et
PHAR Q2 2026 Earnings: Marginal EPS Miss Triggers 15.5% SelloffEarnings Surprise Score - https://www.dars.gov.et/
Pharming Q2 2026 slides: Joenja growth offsets RUCONEST pressure - investing.com
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update - MarketBeat
Pharming Group NV Sponsored ADR Revenue Breakdown – DUS:PHG - TradingView
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by Analysts - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Gap DownHere's What Happened - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Pharming Group N.V - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Pharming Group N.V - The National Law Review
A2QLQY Forecast — Price Target — Prediction for 2027 - TradingView
Pharming Group NV Sponsored ADR Actuals & Estimates (NASDAQ:PHAR) - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
A2QLQY Forecast — Price Target — Prediction for 2027 - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Form 6K Pharming Group NV For: 28 May By Investing.com - Investing.com South Africa
Finanzdaten der Pharming Group Nv Adr-Aktie (PHAR)
Umsatz
Nettogewinn
Free Cashflow
ENV
8.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):